|
|
Middle East Journal of Cancer، جلد ۱۴، شماره ۱، صفحات ۷۳-۸۰
|
|
|
| عنوان فارسی |
|
|
| چکیده فارسی مقاله |
|
|
| کلیدواژه‌های فارسی مقاله |
|
|
| عنوان انگلیسی |
SLC19A1 and Thymidylate Synthase Polymorphisms Do not Predict Survival Outcome in Non-Small-Cell Lung Cancer Treated with Pemetrexed-Cisplatin Chemotherapy Regimen |
|
| چکیده انگلیسی مقاله |
Background: Lung cancer is the leading cause of cancer deaths worldwide. Pharmacogenomics plays an important role in tailoring cancer patients’ treatment. Pemetrexed is widely used in first- and second-line chemotherapy of non-small cell lung cancer (NSCLC); however, there is no available predictive biomarker for pemetrexed treatment. The present study aimed to investigate the role of polymorphisms in thymidylate synthase and SLC19A1 polymorphisms with clinical outcome in patients with advanced NSCLC treated in first-line with pemetrexed or pemetrexed plus cisplatin.Method: This cohort study included 40 metastatic lung cancer patients treated with pemetrexed plus cisplatin. We utilized the tetra-primer amplification refractory mutation system-polymerase chain (ARMS-PCR) reaction for genotyping of rs3788189 and rs1051298. TYMS 28-VNTR and rs16430 were genotyped in the patients via PCR amplification and PCR-RFLP, respectively. Fisher's exact test and Kaplan-Meier curve were used for statistical analysis.Results: We recruited 40 patients in this research with a median age of 58.9 years. The median survival of all the 40 patients was 11.6 months. The overall survival of the patients, as well as their gender, age, and metastatic sites were not found to be statistically associated with rs1051298, rs3788189, TYMS VNTR, and rs16430.Conclusion: Our study did not identify any associations between the SLC19A1 and TYMS VNTR and rs16430 and clinical outcomes in advanced NSCLC patients. However, further investigation will be conducive to finding effective clinical biomarkers for the treatment of patients with NSCLC. |
|
| کلیدواژه‌های انگلیسی مقاله |
Non-small cell lung cancer, Thymidylate synthase, SLC19A, Pemetrexed, Polymorphism |
|
| نویسندگان مقاله |
Mohammad Hadi Abbasian |
Department of Medical Genetics, National Institute for Genetic Engineering and
Biotechnology, Tehran, Iran
Nafiseh Ansarinejad |
Department of Hematology and Oncology, Hazrat Rasool-e Akram Hospital, Iran
University of Medical Sciences, Tehran, Iran
Tayeb Ramim |
Department of Health Information Management, School of Health Management and
Information Sciences, Iran University of Medical Sciences, Tehran, Iran
Farshid Fardad |
Department of Hematology and Oncology, Hazrat Rasool-e Akram Hospital, Iran
University of Medical Sciences, Tehran, Iran
Bahareh Abbasi |
Department of Medical Genetics, National Institute for Genetic Engineering and
Biotechnology, Tehran, Iran
|
|
| نشانی اینترنتی |
https://mejc.sums.ac.ir/article_48279_6906424d8d389efe87089f7d09f4c56e.pdf |
| فایل مقاله |
فایلی برای مقاله ذخیره نشده است |
| کد مقاله (doi) |
|
| زبان مقاله منتشر شده |
en |
| موضوعات مقاله منتشر شده |
|
| نوع مقاله منتشر شده |
|
|
|
|
برگشت به:
صفحه اول پایگاه |
نسخه مرتبط |
نشریه مرتبط |
فهرست نشریات
|